AQR Capital Management
FDMT icon

AQR Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

AQR Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$669K Buy
50,281
+4,504
+10% +$43.9K ﹤0.01% 3241
2026
Q1 		$426K Buy
45,777
+9,693
+27% +$84.4K ﹤0.01% 3214
2025
Q4 		$271K Buy
36,084
+180
+0.5% +$1.83K ﹤0.01% 3215
2025
Q3 		$312K Buy
35,904
+9,843
+38% +$58.8K ﹤0.01% 3063
2025
Q2 		$96.7K Buy
26,061
+11,721
+82% +$41.2K ﹤0.01% 3182
2025
Q1 		$46.3K Buy
+14,340
New +$67.6K ﹤0.01% 3084

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

AQR Capital Management's FDMT Position: Q2 2026 in Review

AQR Capital Management increased its 4D Molecular Therapeutics (FDMT) stake by 9.8% in Q2 2026, buying an estimated $43.9K and bringing the position to 50,281 shares worth $669K. The position accounts for ﹤0.01% of the portfolio, ranked #3241.

AQR Capital Management first reported a position in FDMT in Q1 2025 and has held it in 6 quarters since. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • AQR Capital Management held 50,281 shares of 4D Molecular Therapeutics worth $669K as of Q2 2026.
  • AQR Capital Management bought 4,504 4D Molecular Therapeutics shares in Q2 2026, an estimated $43.9K.
  • 4D Molecular Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #3241 holding.
  • AQR Capital Management first reported a position in 4D Molecular Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.